Iris Parent Holding CORP 10-Q quarterly reports

Liminatus Pharma, Inc. filed its Q2 2026 Form 10-Q, detailing continued operational losses, a substantial accumulated deficit, and ongoing efforts to regain Nasdaq listing compliance.

Liminatus Pharma reports a net loss of $1.12 million for Q1 2026 while highlighting ongoing efforts to regain Nasdaq compliance.

Liminatus Pharma, a pre-clinical biopharmaceutical company, reported significant losses and a going concern warning in its Q3 2025 filing, despite a recent business combination and capital raise.

Liminatus Pharma, Inc. reported its Q2 2025 results, highlighting its recent Nasdaq listing, significant debt-to-equity conversions, and ongoing going concern doubts despite a net income for the quarter.

Liminatus Pharma, Inc. (formerly Iris Parent Holding Corp.) has successfully completed its business combination, leading to its Nasdaq listing, but the company's financial statements raise substantial doubt about its ability to continue as a going concern.